31.05.2023 - WILMINGTON, Del., May 31, 2023 (GLOBE NEWSWIRE) - Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Jefferies Healthcare Conference, .
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Prelude Therapeutics (NASDAQ:PRLD – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. It is focused on discovering and developing small molecule therapies optimized to […]